全球首创采用iNSC为神经系统疾病干细胞疗法的种子细胞

全球首个完成iNSC-DAP帕金森细胞疗法研究者发起临床试验（IIT ）随访一年，成果积极

追求安全、长效神经系统疾病干细胞新疗法

北京慧心医谷生物科技有限责任公司成立于2021年7月，此前，我们的科学家们深耕干细胞再生医学治疗领域的研究已十年有余。我们致力于将拥有自主知识产权的国际领先的细胞重编程技术、基因治疗技术应用于神经系统疾病的药物研究以及创新疗法的开发

目前，我们已建立三大核心技术平台，分别为细胞重编程平台、诱导神经干细胞（induced neural stem cells, iNSCs）分化平台，以及类器官分化平台。基于此三大技术平台，开辟神经性疾病的创新疗法的未来

首个在研创新药是利用诱导神经干细胞（iNSCs）分化成多巴胺能神经前体细胞（iNSC-DAP），经颅内注射，精准修复受损神经细胞，旨在从根本上终止或延缓帕金森病（PD）的进程。该项目目前进度处于国际第一梯队，安全性更高，制备周期短，可以应用于自体和异体移植

2022年3月，公司建于北京中关村生命科学园的GMP级别细胞制品生产车间正式投入使用，开展国家药监局药物临床试验申请（即IND申报）相关研究工作

2023年7月18日，全球首例使用iNSC-DAP（诱导神经干细胞来源的多巴胺能神经前体细胞）自体细胞移植治疗帕金森病的神经外科手术在首都医科大学宣武医院成功完成。随访12个月，取得良好的安全性和有效性。

The world's first seed cell to use iNSC for stem cell therapy for neurological diseases； The world's first researcher to complete iNSC-DAP Parkinson's cell therapy initiated a clinical trial (IIT) for one year of follow-up, with positive results； Pursuing safe, long-lasting new stem cell therapies for neurological diseases

Wiseheart MedVal Biotech Co., Ltd. was established in July 2021. Prior to this, our scientists had been deeply involved in research in the field of stem cell regenerative medicine treatment for more than ten years. We are committed to applying internationally leading cell reprogramming technology and gene therapy technology with independent intellectual property rights to drug research on neurological diseases and the development of innovative therapies.

At present, we have established three core technology platforms, namely the cell reprogramming platform, the induced neural stem cell (iNSCs) differentiation platform, and the organoid differentiation platform. Based on these three major technology platforms, we will open up the future of innovative treatments for neurological diseases. The first innovative drug under development uses induced neural stem cells (iNSCs) to differentiate into dopaminergic neural precursor cells (iNSC-DAP), which can be injected intracranially to precisely repair damaged nerve cells, aiming to fundamentally terminate or delay Parkinson's disease. disease (PD) progression. The current progress of this project is in the first echelon in the world. It is safer and has a short preparation cycle. It can be used in autologous and allogeneic transplantation. In March 2022, the company's GMP-like cell product production workshop built in Beijing Zhongguancun Life Science Park was officially put into use, and research work related to the National Food and Drug Administration's drug clinical trial application (i.e. IND application) was carried out. On July 18, 2023, the world's first neurosurgery using iNSC-DAP (induced neural stem cell-derived dopaminergic neural precursor cells) autologous cell transplantation to treat Parkinson's disease was successfully completed at Xuanwu Hospital of Capital Medical University. The 12-month follow-up showed good safety and effectiveness.

以科学之慧，以仁爱之心，治疾病之本

With the wisdom of science , and the heart of benevolence, cure the root causes of diseases.